Y-mabs schedules FDA meeting on delayed cancer drug for October

The Danish-American biotech company will meet with the US health authorities next month to review the submission for cancer candidate omburtamab.

Photo: Kelly Davidson Photography

Next month, Y-mabs will meet with the US Food and Drug Administration (FDA) to review the company’s resubmission of drug candidate omburtamab, the Danish-American company reported in a press release last week.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs